B2M and plasma cell myeloma: Gossypol also upregulates expression of proteins associated with antigen presenting pathways including HLA classes I and II histocompatibility antigens and beta-2-microglobulin that may elicit immune responses and be developed into a new therapeutic approach for multiple myeloma treatment.